Loading...
PhD Martin Tretjak

PhD Martin Tretjak
no.: 34754 source: ARIS

researcher – active in research organisation
Foreign language skills
Research activity

Code Science Field Subfield
3.06.00  Medical sciences  Cardiovascular system   
3.07.00  Medical sciences  Metabolic and hormonal disorders   
Points
47.1
A''
0
A'
40.04
A1/2
40.04
CI10
18
CImax
7
h10
3
A1
0.19
A3
0
Data for the last 5 years (citations for the last 10 years) on October 15, 2025; Data for score A3 calculation refer to period 2020-2024
Data for ARIS tenders ( 23.05.2022 – Target research programmes, archive )
Database Linked records Citations Pure citations Average pure citations
WoS 10  56  53  5.3 
Scopus 10  66  64  6.4 
Doctoral dissertations and other final papers Show
Obtaining results now
source: COBISS
Employments
source: ARIS
Type of employment Research org. Research group
Full time employment (100%, RD:20%)  General Hospital Slovenj Gradec  Raziskovalna skupina Splošne bolnišnice Slovenj Gradec (Slovene) 
Research projects Legend
source: ARIS
Biography
Undergraduate education: 09/1990 -07/1996: Medical school at University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia Graduate education: 11/2006: Ph.D. degree in Medical Science, University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia Doctoral dissertation: “Assessment of left and right ventricular function using tissue Doppler imaging in healthy elderly” 05/2004: Master of Science degree in Medical Science, University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia Masters thesis: “Assessment of left ventricular function using tissue Doppler imaging in patients with heart failure” Post-graduate training: 12/2001 – present Attending Physician, Medical Intensive Care Unit, Echo laboratory, General Hospital Slovenj Gradec, Slovenia 09/2015 six hour course on Good Clinical Practices (NIDA Clinical Trials Network) 2001, 2005, 2010 International echocardiography courses (basic EAE course, Contrast echocardiography, 4D Echo & Multidimensional imaging) 05/1997 - 12/2001: Resident, Division of Internal Medicine Ljubljana University Medical Center, Ljubljana, Slovenia 09/1996 - 04/1997: Intern, Emergency Medicine General Hospital Slovenj Gradec, Ljubljana, Slovenia Academic Appointments: 04/2006 Assistant, Faculty of medicine, University of Maribor, Slovenia 10/2006 Mentor of Echocardiography, Working group for Echocardiography, Slovenian Society of cardiology, Slovenia Hospital Appointments: 06/2017 - present Attending Physician, Medical Intensive Care Unit, General Hospital Slovenj Gradec, Slovenia 04/2016 – 06/2017 deputy Head of Department of internal medicine, General Hospital Slovenj Gradec 10/2005 – 06/2016 Head of Medical Intensive Care Unit, General Hospital Slovenj Gradec, Slovenia 12/2001-10/2005 Attending Physician, Medical Intensive Care Unit, General Hospital Slovenj Gradec, Slovenia Licensure: 10/2001: Internal Medicine License Ministry of Health, Republic of Slovenia, Ljubljana, Slovenia Professional organizations: 05/2005: European Society of Cardiology 09/1996: Medical Chamber of Slovenia Honors and awards: 05/2007: Young researcher's award in the field of cardiology Slovenian Society of cardiology, Slovenia 12/1996: Oražen Award (the best student in class) University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia 07/1996: Graduation with Honors University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia 10/1993: Plečnik Award (excellent study results) University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia Research: 2010-12: A Multi-center, Open-Label, Randomized Study Evaluating the Safety and Efficacy of Three Dosing Regimens of Replagal Enzyme Replacement Therapy in Adult Patients with Fabry Disease (TKT028); phase 3; investigator 2012-13: An Open-label Extension of Study TKT028 Evaluating Safety and Clinical Outcomes of Replagal Enzyme Replacement Therapy Administered to Adult Patients With Fabry Disease; phase 3; investigator 2018 - : The BALANCE Study - A randomized, double-Blind, Active-control study of the safety and efficacy of pegunigaLsidase alfa compAred to agalsidase beta on reNal funCtion in patiEnts with Fabry disease previously treated with agalsidase beta; phase 3; investigator 2018 - : The BRIDGE Study - An Open Label Study of the Safety and Efficacy of PRX 102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa); phase 3; investigator
We were not given permission by the researcher to publish data.
Views history
Favourite